Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Telomir Pharmaceuticals, Inc. ( (TELO) ) has issued an update.
On June 5, 2025, Telomir Pharmaceuticals announced promising preclinical study results for its lead compound, Telomir-1, in treating Werner Syndrome, a genetic disorder causing accelerated aging. The study demonstrated that Telomir-1 effectively reset biological aging markers, restored healthy DNA methylation, increased telomere length, reversed muscle and weight loss, reduced oxidative stress, and ensured 100% survival in treated animals. These findings suggest Telomir-1’s potential as a novel therapeutic candidate for aging-related diseases, reinforcing the company’s position in age-reversal science.
The most recent analyst rating on (TELO) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.
More about Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. is an emerging leader in the age-reversal science industry, focusing on developing treatments that target the fundamental mechanisms of aging-related diseases. The company is particularly involved in addressing conditions driven by telomere dysfunction and epigenetic instability.
Average Trading Volume: 165,829
Technical Sentiment Signal: Sell
Current Market Cap: $60.72M
See more insights into TELO stock on TipRanks’ Stock Analysis page.